Business news with perspective

NuCube Energy is going public via a $500M SPAC deal to fund its microreactors. Can this high-stakes bet deliver clean power to data centers and industry?

A £1.3M debt dispute escalates as the National Bank of Uzbekistan pursues Solfy CA in English courts, alleging a smear campaign to derail justice.

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

Carolyn Starrett's appointment to the NeoGenomics board signals a major push to integrate AI and real-world data into the core of cancer diagnostics.

Promising 3-year survival data for a novel immunotherapy combo offers new hope for patients with MSS colorectal cancer, a notoriously difficult disease.

Verano's upcoming Q2 report is a key indicator for the cannabis sector. We look at the strategic moves, from stock splits to rescheduling, setting the stage.

With its stock lagging despite strong sales, Insulet brings on a proven value-creator. Can the 'Mazelsky Playbook' accelerate growth and fend off rivals?

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

A new contract goes beyond equipment, revealing a strategic blueprint for Angola's energy sector, local growth, and the future of ultra-deepwater operations.

Lightbridge Corp. hits a critical milestone at Idaho National Lab, moving its advanced nuclear fuel from theory to tangible data. What does this signal mean?

China's data center giant GDS secures a massive war chest and reshuffles its board, signaling an aggressive push to dominate the AI infrastructure boom.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

The lender's 10% yield attracts income investors, but a tight payout ratio and market shifts raise questions about its long-term sustainability.

Triple Flag's US$440M gold stream on Australia's Ravenswood mine is more than a deal. It's a look into the future of mining finance and strategic investment.

A new platform aims to help scam victims reclaim billions. But in the murky world of asset recovery, separating real help from false hope is a critical task.

KKR's accelerated capital returns and a major reporting overhaul reveal a recovering private equity landscape, a crucial sign for tech firms awaiting exits.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Adobe's new enterprise offering isn't just another AI tool; it's a strategic play to solve brand consistency and IP risks at scale. Is it the key to unlocking AI's true potential?